Floatz logo

SRY-BOX TRANSCRIPTION FACTOR 2

Stage IV Lung Cancer AJCC v8

University of Washingtonprotein_peptidePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
81/ 100

Competitive context

303 Active assets in the Stage IV Lung Cancer AJCC v8 cohort.

Asset / SponsorPhaseRating
CIS-DIAMMINEDICHLOROPLATINUM II
University of Vermont
Phase 4BB
Carboplatin
SystImmune Inc.
Phase 4BB
PROPOFOL
Kaohsiung Medical University Chung-Ho Memorial Hospital
Phase 4BB
Nivolumab
University of Chicago
Phase 4BB
Desflurane
Peter MacCallum Cancer Centre, Australia
Phase 4BB

View all 50 →

Same molecule, other indications

SRY-BOX TRANSCRIPTION FACTOR 2 is also rated in:

Her2-receptor negative breast cancerDormant
B
Indicative ·
60 / 100
View asset →
breast cancerDormant
B
Indicative ·
58 / 100
View asset →
hormone receptor-positive breast cancerDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →